


Functional Precision Oncology

Combining Individualized Diagnostics with Rapid Translational Research


Dr. med. Peter-Martin Bruch
Successful R & I in Europe 2026 – 20.02.2026

Functional Precision Oncology

- *Ex vivo* drug response of primary tumor cells
- Prediction of therapy response beyond genetic risk factors
 - Individual off-label treatments
 - Guide between equivalent therapy options
 - Directly play into drug development pipelines



Healthcare Integration



Prediction of individual sensitivity profiles:


- *Ex Vivo* Drug Response & Immune Activation
- Microenvironmental profiling
- Genetic Risk Factors

Scientific and Technological Expertise

Ex Vivo Drug Response & Immune Activation

Hoechst + CD20-PE

Hoechst + CD20-PE




Control

BsAb

Brinkmann et al. Blood 2024
Roider et al. Blood Adv 2021



Microenvironmental profiling

Roider et al. 2024
Bruch et al. 2022




Integration with Genetic Risk Factors & Clinical Implementation

Liebers et al. Nat Cancer 2023; Dietrich et al. NEJM 2012



Intersectoral Cooperation



Previous EP PerMed projects: SYMMETRY (2021-2024), BIALYMP (2022-2025), TRANS-AML-EU (2025-2028)